

Michele Maio

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2549462/michele-maio-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

222
papers

47,445
citations

71
h-index

217
g-index

254
ext. papers

56,519
ext. citations

11
avg, IF

6.68
L-index

#	Paper	IF	Citations
222	Nivolumab plus ipilimumab in melanoma brain metastases.. <i>Lancet Oncology, The</i> , 2022 , 23, e53	21.7	0
221	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101874	2.2	27
220	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 499	3.5	1
219	Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.. <i>European Journal of Cancer</i> , 2022 , 169, 188-197	7.5	0
218	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
217	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2021 ,	7.5	1
216	COVID and Lung Cancer. <i>Current Oncology Reports</i> , 2021 , 23, 134	6.3	4
215	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 655-664	21.7	9
214	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2565-2565	2.2	2
213	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 643-654	21.7	58
212	The pleiotropic role of circular and long noncoding RNAs in cutaneous melanoma. <i>Molecular Oncology</i> , 2021 ,	7.9	2
211	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , 2021 , 27, 4737-4745	12.9	8
210	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 240	12.8	0
209	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. <i>European Journal of Cancer</i> , 2021 , 152, 155-164	7.5	5
208	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 2021 , 9,		4
207	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2914-2925	2.2	20
206	Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. <i>Lancet Respiratory Medicine, the</i> , 2021 , 9, 969-976	35.1	9

205	Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix. <i>European Journal of Cancer</i> , 2021 , 156, 119-121	7.5	0
204	Perspectives of Immunotherapy in Advanced Melanoma: Combinations and Sequencing 2021 , 281-310		
203	SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome. <i>European Journal of Cancer</i> , 2020 , 133, 1-3	7.5	15
202	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020 , 8,		19
201	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020 , 26, 4201-4205	12.9	25
200	Serafino Zappacosta: An Enlightened Mentor and Educator. <i>Frontiers in Immunology</i> , 2020 , 11, 217	8.4	0
199	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. <i>Cancers</i> , 2020 , 12,	6.6	14
198	Challenges in lung cancer therapy during the COVID-19 pandemic. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 542-544	35.1	62
197	Abstract CT270: A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1: The NIBIT-ML1 Study 2020 ,		2
196	Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy. <i>Archives of Endocrinology and Metabolism</i> , 2020 , 64, 483-486	2.2	5
195	Loss of Spry1 reduces growth of BRAF-mutant cutaneous melanoma and improves response to targeted therapy. <i>Cell Death and Disease</i> , 2020 , 11, 392	9.8	5
194	Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1465-1477	21.7	140
193	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3638-3651	2.2	47
192	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 119, 168-178	7.5	32
191	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
190	NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy. <i>International Journal of Cancer</i> , 2019 , 145, 2238-2248	7.5	16
189	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with -mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 3239-3246	12.9	23
188	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019 , 119, 1-10	7.5	79

187	The future of mesothelioma treatment: time to shift gear. <i>Lancet Respiratory Medicine, the</i> , 2019 , 7, 554-555	2
186	Immunotherapy of brain metastases: breaking a "dogma". <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 419	12.8 31
185	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 121, 144-153	7.5 19
184	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7351-7362	12.9 33
183	The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 143-150	7.4 1
182	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 510-520	21.7 123
181	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2 918
180	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF mutation-positive melanoma. <i>British Journal of Cancer</i> , 2018 , 118, 777-784	8.7 14
179	Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13-15, 2016. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1023-1030	7.4 1
178	Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 77-83	5.4 5
177	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018 , 16,	8.5 1
176	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018 , 391, 2128-2139	40 910
175	New horizons from immunotherapy in malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2018 , 10, S322-S332	2.6 7
174	Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1443	5.6 11
173	Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. <i>Lancet Respiratory Medicine, the</i> , 2018 , 6, 451-460	35.1 129
172	Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1317-1324	7.4 4
171	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 393-403	21.7 69
170	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017 , 73, 61-70	7.5 59

169	Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. <i>Endocrine</i> , 2017 , 58, 535-541	4	28
168	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. <i>OncolImmunology</i> , 2017 , 6, e1323618	7.2	31
167	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 611-622	21.7	306
166	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. <i>Oncotarget</i> , 2017 , 8, 48507-48520	3.3	52
165	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1824-1835	59.2	1178
164	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
163	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1261-1273	21.7	266
162	Immunotherapy targeting immune check-point(s) in brain metastases. <i>Cytokine and Growth Factor Reviews</i> , 2017 , 36, 33-38	17.9	7
161	Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. <i>Cytokine and Growth Factor Reviews</i> , 2017 , 36, 25-31	17.9	6
160	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). <i>Cytokine and Growth Factor Reviews</i> , 2017 , 36, 1-3	17.9	0
159	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017 , 23, 1929-1936	12.9	181
158	Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors 2017 ,		5
157	"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 119-267	7.4	
156	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <i>Journal of Translational Medicine</i> , 2016 , 14, 65	8.5	8
155	Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. <i>OncolImmunology</i> , 2016 , 5, e1071007	7.2	18
154	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 2908-18	12.9	372
153	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016 , 126, 921-37	15.9	48
152	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016 , 22, 5487-5496	12.9	373

151	ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2016 , 1393, 133-9	1.4	2
150	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 1845-1855	59.2	870
149	Nivolumab in previously untreated melanoma without BRAF mutation. <i>New England Journal of Medicine</i> , 2015 , 372, 320-30	59.2	3809
148	"Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 131-34	7.4	
147	Immune checkpoint blockade in malignant mesothelioma. <i>Seminars in Oncology</i> , 2015 , 42, 418-22	5.5	8
146	Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 301-9	35.1	148
145	coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). <i>Journal of Translational Medicine</i> , 2015 , 13, O4	8.5	7
144	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. <i>Journal of Translational Medicine</i> , 2015 , 13, O6	8.5	9
143	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 375-84	21.7	1881
142	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 522-30	21.7	842
141	Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1191-6	2.2	334
140	Epigenetics meets immune checkpoints. <i>Seminars in Oncology</i> , 2015 , 42, 506-13	5.5	28
139	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. <i>Future Oncology</i> , 2015 , 11, 1355-62	3.6	4
138	Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. <i>Oncolimmunology</i> , 2015 , 4, e1019978	7.2	46
137	Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. <i>Clinical Cancer Research</i> , 2015 , 21, 4040-7	12.9	75
136	CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 105-12	7.4	17
135	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. <i>Vaccines</i> , 2015 , 3, 420-8	5.3	14
134	The ipilimumab lesson in melanoma: achieving long-term survival. <i>Seminars in Oncology</i> , 2015 , 42, 387-401	5.5	23

133	Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 999-1009	7.4	102
132	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
131	Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. <i>Seminars in Oncology</i> , 2015 , 42, 429-35	5.5	57
130	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015 , 25, 208-24	24.7	126
129	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015 , 26, 798-803	10.3	100
128	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology, The</i> , 2015 , 16, 15-7	21.7	9
127	A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS9090-TPS9090	2.2	5
126	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 109-16	4.8	90
125	Epigenetic drugs as immunomodulators for combination therapies in solid tumors. <i>Pharmacology & Therapeutics</i> , 2014 , 142, 339-50	13.9	74
124	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1867-76	59.2	1403
123	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 30	12.8	76
122	Towards the introduction of the OmnoscoreOn the classification of malignant tumours. <i>Journal of Pathology</i> , 2014 , 232, 199-209	9.4	882
121	Clinical experience with ipilimumab 3mg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014 , 12, 116	8.5	130
120	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , 2014 , 15, 323-32	21.7	753
119	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 700-12	21.7	982
118	Biomarkers for immune checkpoint inhibitors--authorsReply. <i>Lancet Oncology, The</i> , 2014 , 15, e1-2	21.7	3
117	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014 , 50, 121-7	7.5	126
116	Peptide-based vaccines for cancer therapy. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 3175-8	4.4	52

115	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. <i>Cancer Investigation</i> , 2014 , 32, 144-9	2.1	74
114	Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. <i>Clinical Cancer Research</i> , 2014 , 20, 1601-9	13.9	192
113	Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 1389-1396	4.3	2
112	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1056-64	14.4	146
111	Epigenetic markers of prognosis in melanoma. <i>Methods in Molecular Biology</i> , 2014 , 1102, 481-99	1.4	5
110	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , 2014 , 120, 2016-24	6.4	15
109	Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?. <i>Onc Immunology</i> , 2014 , 3, e27482	7.2	15
108	Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma. <i>Clinical Cancer Research</i> , 2014 , 20, 4390-9	12.9	30
107	A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7531-7531	2.2	6
106	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA9008-LBA9008	3.2	13
105	BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9118-TPS9118	2.2	4
104	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 897-908	7.4	28
103	Immunomodulatory activity of SGI-110, a 5-aza-2-Deoxycytidine-containing demethylating dinucleotide. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 605-14	7.4	49
102	Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 616-22	2.2	607
101	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013 , 11, 202	8.5	28
100	Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10mg/kg within an expanded access programme. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1021-8	7.4	103
99	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 1104-1111	21.7	262
98	Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2413-20	2.2	163

97	Update on the role of ipilimumab in melanoma and first data on new combination therapies. <i>Current Opinion in Oncology</i> , 2013 , 25, 166-72	4.2	22
96	Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. <i>International Journal of Cancer</i> , 2013 , 132, 2557-66	7.5	19
95	Epigenetics of melanoma: implications for immune-based therapies. <i>Immunotherapy</i> , 2013 , 5, 1103-16	3.8	13
94	Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma. <i>Dermatology</i> , 2013 , 226 Suppl 1, 22-7	4.4	4
93	Clinical experience with ipilimumab 10mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 82	12.8	16
92	Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9053-9053	2.2	7
91	Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9059-9059	2.2	4
90	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 41-8	7.4	104
89	Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. <i>Journal of Translational Medicine</i> , 2012 , 10, 185	8.5	35
88	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012 , 10, 205	8.5	538
87	Thymosin β 1 in melanoma: from the clinical trial setting to the daily practice and beyond. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1270, 8-12	6.5	13
86	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2012 , 13, 879-86	21.7	232
85	The cost of unresectable stage III or stage IV melanoma in Italy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012 , 31, 91	12.8	20
84	Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1835-41	2.2	99
83	Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. <i>Clinical Cancer Research</i> , 2012 , 18, 6485-96	12.9	53
82	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8502-8502	2.2	65
81	The biology of cancer testis antigens: putative function, regulation and therapeutic potential. <i>Molecular Oncology</i> , 2011 , 5, 164-82	7.9	222
80	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>New England Journal of Medicine</i> , 2011 , 364, 2517-26	59.2	3396

79	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
78	Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 467-77	7.4	72
77	Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. <i>Journal of Translational Medicine</i> , 2011 , 9, 78	8.5	45
76	Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2011 , 226, 2595-600	7	14
75	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. <i>Clinical Cancer Research</i> , 2011 , 17, 3064-76	12.9	87
74	CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. <i>PLoS ONE</i> , 2010 , 5, e15183	3.7	61
73	Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1780-7	2.2	52
72	Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. <i>Cardiovascular Research</i> , 2010 , 86, 12-9	9.9	130
71	Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. <i>Journal of Translational Medicine</i> , 2010 , 8, 56	8.5	79
70	CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. <i>Journal of Immunotherapy</i> , 2010 , 33, 810-6	5	18
69	Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 487-8	7.4	4
68	Biology and clinical applications of CD40 in cancer treatment. <i>Seminars in Oncology</i> , 2010 , 37, 517-23	5.5	37
67	Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. <i>Seminars in Oncology</i> , 2010 , 37, 460-7	5.5	47
66	The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. <i>Seminars in Oncology</i> , 2010 , 37, 499-507	5.5	201
65	Anti-CTLA-4 antibody adjuvant therapy in melanoma. <i>Seminars in Oncology</i> , 2010 , 37, 455-9	5.5	33
64	Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. <i>Seminars in Oncology</i> , 2010 , 37, 468-72	5.5	27
63	Introduction to Immunologic Checkpoints for Cancer Treatment: From Scientific Rationale to Clinical Application. <i>Seminars in Oncology</i> , 2010 , 37, 429	5.5	2
62	Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. <i>Journal of Cellular Physiology</i> , 2010 , 223, 352-8	7	18

61	High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. <i>PLoS ONE</i> , 2009 , 4, e5219	3.7	650
60	Epigenetically regulated tumor-associated antigens in melanoma. <i>Expert Review of Dermatology</i> , 2009 , 4, 145-154		1
59	Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. <i>Clinical Cancer Research</i> , 2009 , 15, 7412-20	12.9	2380
58	Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1297-306	7.4	203
57	Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. <i>Cancer Research</i> , 2008 , 68, 122-31	10.1	39
56	The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level. <i>Tumori</i> , 2008 , 94, 179-181	1.7	3
55	Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. <i>Journal of Cellular Physiology</i> , 2008 , 215, 287-91	7	51
54	Endoglin (CD105): A Strong Candidate for Immunologic Targeting of Tumor Neovasculature in Human Malignancies 2008 , 395-410		
53	Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. <i>Journal of Cellular Physiology</i> , 2007 , 212, 330-44	7	107
52	Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. <i>Clinical Cancer Research</i> , 2007 , 13, 3333-8	12.9	101
51	5-AZA-2-deoxycytidine in cancer immunotherapy: a mouse to man story. <i>Cancer Research</i> , 2007 , 67, 2900-1; author reply 2901-2	10.1	21
50	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 958-68	7.4	116
49	Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2006 , 207, 58-66	7	46
48	The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. <i>Clinical Cancer Research</i> , 2006 , 12, 3297-305	12.9	34
47	Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. <i>Seminars in Oncology</i> , 2005 , 32, 473-8	5.5	42
46	Epigenetic immunomodulation of hematopoietic malignancies. <i>Seminars in Oncology</i> , 2005 , 32, 503-10	5.5	17
45	Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2005 , 202, 474-7	7	22
44	Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients. <i>Women's Oncology Review</i> , 2005 , 5, 19-21		

43	Heat shock proteins and their use as anticancer vaccines. <i>Clinical Cancer Research</i> , 2004 , 10, 8142-6	12.9	56
42	Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2-deoxycytidine. <i>Cancer Research</i> , 2004 , 64, 9167-71	10.1	172
41	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 227-33	7.4	108
40	Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. <i>Journal of Cellular Physiology</i> , 2004 , 200, 272-6	7	6
39	Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. <i>Journal of Translational Medicine</i> , 2004 , 2, 18	8.5	114
38	Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 748-54	5.6	55
37	5-Aza-2-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. <i>Blood</i> , 2003 , 101, 4644-6; discussion 4645-6	2.2	75
36	Methylation-regulated expression of HLA class I antigens in melanoma. <i>International Journal of Cancer</i> , 2003 , 105, 430-1; author reply 432-3	7.5	34
35	Differential levels of soluble endoglin (CD105) in myeloid malignancies. <i>Journal of Cellular Physiology</i> , 2003 , 194, 171-5	7	44
34	Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. <i>Oncogene</i> , 2003 , 22, 6557-63	9.2	192
33	Epigenetic targets for immune intervention in human malignancies. <i>Oncogene</i> , 2003 , 22, 6484-8	9.2	62
32	Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?. <i>Oncogene</i> , 2003 , 22, 6564-9	9.2	41
31	Introduction: Melanoma: American and European perspectives on diagnosis and treatment. <i>Seminars in Oncology</i> , 2002 , 29, 306-7	5.5	
30	European approach to antibody-based immunotherapy of melanoma. <i>Seminars in Oncology</i> , 2002 , 29, 471-8	5.5	1
29	Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells. <i>Journal of Cellular Physiology</i> , 2002 , 190, 200-6	7	5
28	Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2002 , 51, 9-14	7.4	35
27	Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4169-80	8.2	326
26	Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. <i>Journal of Immunotherapy</i> , 2002 , 25, 16-26	5	104

25	5-aza-2-Deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. <i>Clinical Cancer Research</i> , 2002 , 8, 2690-5	12.9	105
24	Unbalanced expression of HLA-A and -B antigens: a specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-gamma. <i>International Journal of Cancer</i> , 2001 , 91, 500-7	7.5	10
23	Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. <i>Journal of Cellular Physiology</i> , 2001 , 188, 1-7	7	148
22	Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies. <i>Frontiers in Bioscience - Landmark</i> , 2001 , 6, D776-84	2.8	4
21	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN- 2001 , 91, 500		1
20	Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. <i>Journal of Cellular Physiology</i> , 2000 , 185, 317-23	7	25
19	Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. <i>Human Gene Therapy</i> , 1999 , 10, 2907-16	4.8	52
18	Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions. <i>Breast Cancer Research and Treatment</i> , 1999 , 58, 19-23	4.4	16
17	In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. <i>Cancer Immunology, Immunotherapy</i> , 1999 , 48, 132-8	7.4	8
16	The overlooked "nonclassical" functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells. <i>Journal of Cellular Physiology</i> , 1999 , 179, 251-6	7	19
15	Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2-Deoxycytidine (5-AZA-CdR). <i>Journal of Immunotherapy</i> , 1999 , 22, 16-24	5	114
14	Pregnancy and malignant neoplasms of the head and neck. <i>Annals of Otology, Rhinology and Laryngology</i> , 1998 , 107, 991-8	2.1	18
13	Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. <i>Cancer Immunology, Immunotherapy</i> , 1997 , 44, 197-203	7.4	61
12	Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. <i>Human Gene Therapy</i> , 1996 , 7, 1955-63	4.8	71
11	Melanoma-associated hypopigmentation: where are the antibodies?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996 , 19, 613-8	2.7	15
10	Signaling by HLA class II antigens on B cells. <i>Trends in Immunology</i> , 1995 , 16, 548		4
9	Expression and functional role of CD54/Intercellular Adhesion Molecule-1 (ICAM-1) on human blood cells. <i>Leukemia and Lymphoma</i> , 1992 , 8, 23-33	1.9	24
8	Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10. <i>Cancer Immunology, Immunotherapy</i> , 1989 , 30, 34-42	7.4	6

7	Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. <i>International Journal of Cancer</i> , 1989 , 44, 554-9	7.5	27
6	HLA and prognostic factors in primary breast cancer. <i>International Journal of Cancer</i> , 1985 , 35, 581-5	7.5	12
5	The association between congenital adrenal hyperplasia and HLA in Southern Italy. <i>Annals of the New York Academy of Sciences</i> , 1985 , 458, 46-51	6.5	3
4	Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2-Deoxycytidine. <i>Lancet, The</i> , 1984 , 2, 867-8	4.0	52
3	Strong association between an HLA-DR antigen and thyroid carcinoma. <i>Tissue Antigens</i> , 1982 , 20, 155-8		38
2	Epigenetically-Regulated Therapeutic Tumor-Associated Antigens143-160		
1	Epigenetic Mechanisms in Cancer Formation and Progression253-298		2